Opioid use disorder (OUD) has become a mounting public health crisis in the US, often disproportionately affecting individuals in the most vulnerable socioeconomic statuses.

Ascletis Pharma has dosed the first obese or overweight subjects in the 13-week, multi-centre US Phase IIa trial of ASC30.

Organon is terminating development of its endometriosis drug after the Phase II trial failed to show any benefit. The ELENA proof-of-concept study (NCT05560646) was evaluating Organon’s therapy, ...

Bio-Thera Solutions has announced the early termination of its pivotal Phase II/III clinical trial of BAT4406F for NMOSD.

The recent Westminster Health Forum included UK health specialists who discussed the benefit, risk and complications of creating a single, patient data system. Image credit: Marbury / Shutterstock.